|
|
|
|
|
|
|
|
|
|
|
18.05.26 - 22:09
|
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire EN)
|
|
|
BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY....
|
|
|
|
|
|
|
|
|
12.03.26 - 12:03
|
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum (GlobeNewswire EN)
|
|
|
BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026....
|
|
|
|
|
|
|
|
|
04.03.26 - 13:03
|
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference (GlobeNewswire EN)
|
|
|
BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL....
|
|
|
26.01.26 - 13:03
|
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 (GlobeNewswire EN)
|
|
|
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026 at 10:30 AM ET featuring Gregory Strauss, PhD (Franklin Professor of Psychology, University of Georgia) and Brian Kirkpatrick, MD, MSPH (Peters Professor of Psychiatry, University of Arkansas for Medical Sciences). They will join the company management team to elaborate on the patient burden of the negative symptoms of schizophrenia, the challenges associated with assessing negative symptoms in the current regulatory environment and how the company's upcoming Phase 3 trial of roluperidone is expected to meet those challenges....
|
|
|
|
|
|
|
|
|
21.10.25 - 17:45
|
Minerva Neurosciences: NBC-Tipp wird zum Tenbagger! (Sharedeals)
|
|
|
Anfang des Monats berichteten wir über hohe Preissprünge bei der Aktie von Minerva Neurosciences. Jetzt ist klar: Das anfängliche Kursspektakel bei der Biotech-Empfehlung des No Brainer Club war lediglich ein Vorbote – die große Party folgt heute. Von 1,15 US$ auf 12,46 US$ Das kleine Biotechunternehmen Minerva, das im NBC mit einer Kaufzone bis 2,00 […]
The post Minerva Neurosciences: NBC-Tipp wird zum Tenbagger! first appeared on sharedeals.de....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
